Characterization of Ancestral Origin of Cystic Fibrosis of Patients with New Reported Mutations in CFTR

Table 1

Percentage of the ancestral composition of each individual under study.

Patient	AFR	EUR	NAM	Mutation	Mutations’ reference
01	24.6	16.7	58.7	c.1473T>A:p.Cys491	[18]
02	7.6	43.5	48.9	c.2672del:p.Asp891Alafs15	[18]
03	21.6	14.8	63.6	c.2672del:p.Asp891Alafs15	[18]
04	16	42.2	41.8	c.2672del:p.Asp891Alafs15	[18]
05	9.1	8.9	82	c.1486T>C:p.Trp496Arg	[18]
06	22.5	39.6	37.9	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]
07	7.2	55.3	37.5	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]
08	28.2	31.9	39.9	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]
09	5	58.7	36.3	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]
10	11.9	37.2	50.9	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]
11	9.3	32.1	58.6	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]
12	11	25.7	63.3	[c.757G>A:p.Gly253Arg; c.1352G>T:p.Gly451Val]	[18]

AFR: African ancestry; EUR: European ancestry; NAM: Native American ancestry.